Jared M Odegard
Overview
Explore the profile of Jared M Odegard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
678
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Odegard J, Othman A, Lin K, Wang A, Nazareno J, Yoon O, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38604815
Background: Checkpoint inhibitors targeting the programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) pathway are effective therapies in a range of immunogenic cancer types. Blocking this pathway...
2.
Speake C, Skinner S, Berel D, Whalen E, Dufort M, Chad Young W, et al.
JCI Insight
. 2019 Nov;
4(23).
PMID: 31671072
At diagnosis, most people with type 1 diabetes (T1D) produce measurable levels of endogenous insulin, but the rate at which insulin secretion declines is heterogeneous. To explain this heterogeneity, we...
3.
James E, Abreu J, McGinty J, Odegard J, Fillie Y, Hocter C, et al.
Diabetologia
. 2017 Dec;
61(3):658-670.
PMID: 29196783
Aims/hypothesis: Validated biomarkers are needed to monitor the effects of immune intervention in individuals with type 1 diabetes. Despite their importance, few options exist for monitoring antigen-specific T cells. Previous...
4.
Odegard J, Flynn P, Campbell D, Robbins S, Dong L, Wang K, et al.
Vaccine
. 2015 Nov;
34(1):101-9.
PMID: 26571309
Background/objectives: There is currently no licensed prophylactic or therapeutic vaccine for HSV-2 infection. Methods: We developed a novel preclinical vaccine candidate, G103, consisting of three recombinantly expressed HSV-2 proteins (gD...
5.
Speake C, Odegard J
Biomark Insights
. 2015 Oct;
10(Suppl 4):19-24.
PMID: 26462120
Recognizing an increasing need for biomarkers that predict clinical outcomes in type 1 diabetes (T1D), JDRF, a major funding organization for T1D research, recently instituted the Core for Assay Validation...
6.
Odegard J, Nepom G, Wambre E
Clin Immunol
. 2015 Jul;
161(1):44-50.
PMID: 26122171
Allergy and type 1 diabetes are immune mediated diseases that, despite being etiologically distinct, each have inappropriate activation and effector function of antigen-specific T cells in the pathogenic process. Understanding...
7.
Odegard J, Kelley-Clarke B, Tareen S, Campbell D, Flynn P, Nicolai C, et al.
J Immunother
. 2015 Feb;
38(2):41-53.
PMID: 25658613
Dendritic cells (DCs) are essential antigen-presenting cells for the initiation of cytotoxic T-cell responses and therefore attractive targets for cancer immunotherapy. We have developed an integration-deficient lentiviral vector termed ID-VP02...
8.
Mason M, Speake C, Gersuk V, Nguyen Q, Obrien K, Odegard J, et al.
Diabetes
. 2014 Jan;
63(5):1789-95.
PMID: 24430436
Complement component C4 (C4) is a highly variable complement pathway gene situated ∼500 kb from DRB1 and DQB1, the genes most strongly associated with many autoimmune diseases. Variations in C4...
9.
Tareen S, Kelley-Clarke B, Nicolai C, Cassiano L, Nelson L, Slough M, et al.
Mol Ther
. 2014 Jan;
22(3):575-587.
PMID: 24419083
As sentinels of the immune system, dendritic cells (DCs) play an essential role in regulating cellular immune responses. One of the main challenges of developing DC-targeted therapies includes the delivery...
10.
Tareen S, Nicolai C, Campbell D, Flynn P, Slough M, Vin C, et al.
Biores Open Access
. 2014 Jan;
2(6):421-30.
PMID: 24380052
Lentiviral vectors (LVs) are being developed for clinical use in humans for applications including gene therapy and immunotherapy. A safety concern for use of LVs in humans is the generation...